SAPHO: has the time come for tailored therapy?

• Autor(a) principal: Figueiredo, AS
• Data de Publicação: 2020
• Outros Autores: Oliveira, AL, Caetano, A, Moraes-Fontes, MF
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: http://hdl.handle.net/10400.17/3467
• topic: Anti-IL-1 agents; Anti-IL-12/IL-23 agents; Anti-IL-6 agents; Anti-TNF-α agents; SAPHO Syndrome, treatment; HCC IMA; HCC DAUTOIM

SAPHO (synovitis, acne, pustulosis, hyperostosis and osteitis) syndrome is a heterogeneous condition combining osteoarticular and cutaneous manifestations. Conventional treatments are mostly ineffective. We hereby report two patients, the first with an aggressive form of disease and the second with an incomplete response to two different anti-TNF-α agents. Both were successfully treated with tocilizumab and ustekinumab, respectively, over a long period of time. A narrative review of a biological therapy in SAPHO syndrome yielded very little information on the specific use of these agents. We highlight the advantages of personalising therapy and describe emerging promising treatments for this disease.